Loading…

The Progress and Future of US Newborn Screening

Progress in newborn screening (NBS) has been driven for 60 years by developments in science and technology, growing consumer advocacy, the actions of providers involved in the care of rare disease patients, and by federal and State government funding and policies. With the current explosion of clini...

Full description

Saved in:
Bibliographic Details
Published in:International journal of neonatal screening 2022-07, Vol.8 (3), p.41
Main Authors: Watson, Michael S, Lloyd-Puryear, Michele A, Howell, R Rodney
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c475t-3f120bf3b03b9443647c1933df67c375a709bec62bf274c34fb516002de293983
cites cdi_FETCH-LOGICAL-c475t-3f120bf3b03b9443647c1933df67c375a709bec62bf274c34fb516002de293983
container_end_page
container_issue 3
container_start_page 41
container_title International journal of neonatal screening
container_volume 8
creator Watson, Michael S
Lloyd-Puryear, Michele A
Howell, R Rodney
description Progress in newborn screening (NBS) has been driven for 60 years by developments in science and technology, growing consumer advocacy, the actions of providers involved in the care of rare disease patients, and by federal and State government funding and policies. With the current explosion of clinical trials of treatments for rare diseases, the pressure for expansion has grown, and concerns about the capacity for improvement and growth are being expressed. Genome and exome sequencing (GS/ES) have now opened more opportunities for early identification and disease prevention at all points in the lifespan. The greatest challenge facing NBS stems from the conditions most amenable to screening, and new treatment development is that we are screening for rare genetic diseases. In addition, understanding the spectrum of severity requires vast amounts of population and genomic data. We propose recommendations on improving the NBS system and addressing specific demands to grow its capacity by: better defining the criteria by which screening targets are established; financing the NBS system's responsiveness to opportunities for expansion, including engagement and funding from stakeholders; creating a national quality assurance, data, IT, and communications infrastructure; and improving intra-governmental communications. While our recommendations may be specific to the United States, the underlying issues should be considered when working to improve NBS programs globally.
doi_str_mv 10.3390/ijns8030041
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_effae7a4000a43fc8f581638bb840b54</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_effae7a4000a43fc8f581638bb840b54</doaj_id><sourcerecordid>2695288642</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-3f120bf3b03b9443647c1933df67c375a709bec62bf274c34fb516002de293983</originalsourceid><addsrcrecordid>eNpdkV1LHDEUhofSUsV61fsy0JuCbE1y8nlTKFJbQWpBhd6FJHOyzjKb2GSm4r93tmtl9SoheXh4z3mb5j0lnwEMOe5XqWoChHD6qtlnnJiFoOL36537XnNY64oQQgVXoOBtswdCG8YV3W-Or26w_VXysmCtrUtdezqNU8E2x_b6sv2Jdz6X1F6Ggpj6tHzXvIluqHj4eB4016ffrk5-LM4vvp-dfD1fBK7EuIBIGfERPAFvOAfJVaAGoItSBVDCKWI8Bsl8ZIoH4NELKglhHTIDRsNBc7b1dtmt7G3p167c2-x6--8hl6V1ZezDgBZjdKgcnyd0HGLQUWgqQXuvOfGCz64vW9ft5NfYBUxjccMz6fOf1N_YZf5rDTApGZsFnx4FJf-ZsI523deAw-AS5qlaJo1gWku-QT--QFd5KmlelWWKSiGIMhvqaEuFkmstGJ_CUGI3vdqdXmf6w27-J_Z_i_AAn4GbmQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2716550792</pqid></control><display><type>article</type><title>The Progress and Future of US Newborn Screening</title><source>PubMed (Medline)</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Coronavirus Research Database</source><creator>Watson, Michael S ; Lloyd-Puryear, Michele A ; Howell, R Rodney</creator><creatorcontrib>Watson, Michael S ; Lloyd-Puryear, Michele A ; Howell, R Rodney</creatorcontrib><description>Progress in newborn screening (NBS) has been driven for 60 years by developments in science and technology, growing consumer advocacy, the actions of providers involved in the care of rare disease patients, and by federal and State government funding and policies. With the current explosion of clinical trials of treatments for rare diseases, the pressure for expansion has grown, and concerns about the capacity for improvement and growth are being expressed. Genome and exome sequencing (GS/ES) have now opened more opportunities for early identification and disease prevention at all points in the lifespan. The greatest challenge facing NBS stems from the conditions most amenable to screening, and new treatment development is that we are screening for rare genetic diseases. In addition, understanding the spectrum of severity requires vast amounts of population and genomic data. We propose recommendations on improving the NBS system and addressing specific demands to grow its capacity by: better defining the criteria by which screening targets are established; financing the NBS system's responsiveness to opportunities for expansion, including engagement and funding from stakeholders; creating a national quality assurance, data, IT, and communications infrastructure; and improving intra-governmental communications. While our recommendations may be specific to the United States, the underlying issues should be considered when working to improve NBS programs globally.</description><identifier>ISSN: 2409-515X</identifier><identifier>EISSN: 2409-515X</identifier><identifier>DOI: 10.3390/ijns8030041</identifier><identifier>PMID: 35892471</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Automation ; clinical trials ; Genes ; Genetic disorders ; Genetic testing ; Genetics ; Genomes ; Information systems ; Medical screening ; Metabolism ; Molecular biology ; Newborn babies ; newborn screening ; Phenylketonuria ; Public health ; public health policy ; Rare diseases ; Research centers ; Review ; Sickle cell disease ; Task forces</subject><ispartof>International journal of neonatal screening, 2022-07, Vol.8 (3), p.41</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-3f120bf3b03b9443647c1933df67c375a709bec62bf274c34fb516002de293983</citedby><cites>FETCH-LOGICAL-c475t-3f120bf3b03b9443647c1933df67c375a709bec62bf274c34fb516002de293983</cites><orcidid>0000-0001-7776-9123</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2716550792?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2716550792?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35892471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Watson, Michael S</creatorcontrib><creatorcontrib>Lloyd-Puryear, Michele A</creatorcontrib><creatorcontrib>Howell, R Rodney</creatorcontrib><title>The Progress and Future of US Newborn Screening</title><title>International journal of neonatal screening</title><addtitle>Int J Neonatal Screen</addtitle><description>Progress in newborn screening (NBS) has been driven for 60 years by developments in science and technology, growing consumer advocacy, the actions of providers involved in the care of rare disease patients, and by federal and State government funding and policies. With the current explosion of clinical trials of treatments for rare diseases, the pressure for expansion has grown, and concerns about the capacity for improvement and growth are being expressed. Genome and exome sequencing (GS/ES) have now opened more opportunities for early identification and disease prevention at all points in the lifespan. The greatest challenge facing NBS stems from the conditions most amenable to screening, and new treatment development is that we are screening for rare genetic diseases. In addition, understanding the spectrum of severity requires vast amounts of population and genomic data. We propose recommendations on improving the NBS system and addressing specific demands to grow its capacity by: better defining the criteria by which screening targets are established; financing the NBS system's responsiveness to opportunities for expansion, including engagement and funding from stakeholders; creating a national quality assurance, data, IT, and communications infrastructure; and improving intra-governmental communications. While our recommendations may be specific to the United States, the underlying issues should be considered when working to improve NBS programs globally.</description><subject>Automation</subject><subject>clinical trials</subject><subject>Genes</subject><subject>Genetic disorders</subject><subject>Genetic testing</subject><subject>Genetics</subject><subject>Genomes</subject><subject>Information systems</subject><subject>Medical screening</subject><subject>Metabolism</subject><subject>Molecular biology</subject><subject>Newborn babies</subject><subject>newborn screening</subject><subject>Phenylketonuria</subject><subject>Public health</subject><subject>public health policy</subject><subject>Rare diseases</subject><subject>Research centers</subject><subject>Review</subject><subject>Sickle cell disease</subject><subject>Task forces</subject><issn>2409-515X</issn><issn>2409-515X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkV1LHDEUhofSUsV61fsy0JuCbE1y8nlTKFJbQWpBhd6FJHOyzjKb2GSm4r93tmtl9SoheXh4z3mb5j0lnwEMOe5XqWoChHD6qtlnnJiFoOL36537XnNY64oQQgVXoOBtswdCG8YV3W-Or26w_VXysmCtrUtdezqNU8E2x_b6sv2Jdz6X1F6Ggpj6tHzXvIluqHj4eB4016ffrk5-LM4vvp-dfD1fBK7EuIBIGfERPAFvOAfJVaAGoItSBVDCKWI8Bsl8ZIoH4NELKglhHTIDRsNBc7b1dtmt7G3p167c2-x6--8hl6V1ZezDgBZjdKgcnyd0HGLQUWgqQXuvOfGCz64vW9ft5NfYBUxjccMz6fOf1N_YZf5rDTApGZsFnx4FJf-ZsI523deAw-AS5qlaJo1gWku-QT--QFd5KmlelWWKSiGIMhvqaEuFkmstGJ_CUGI3vdqdXmf6w27-J_Z_i_AAn4GbmQ</recordid><startdate>20220718</startdate><enddate>20220718</enddate><creator>Watson, Michael S</creator><creator>Lloyd-Puryear, Michele A</creator><creator>Howell, R Rodney</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7776-9123</orcidid></search><sort><creationdate>20220718</creationdate><title>The Progress and Future of US Newborn Screening</title><author>Watson, Michael S ; Lloyd-Puryear, Michele A ; Howell, R Rodney</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-3f120bf3b03b9443647c1933df67c375a709bec62bf274c34fb516002de293983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Automation</topic><topic>clinical trials</topic><topic>Genes</topic><topic>Genetic disorders</topic><topic>Genetic testing</topic><topic>Genetics</topic><topic>Genomes</topic><topic>Information systems</topic><topic>Medical screening</topic><topic>Metabolism</topic><topic>Molecular biology</topic><topic>Newborn babies</topic><topic>newborn screening</topic><topic>Phenylketonuria</topic><topic>Public health</topic><topic>public health policy</topic><topic>Rare diseases</topic><topic>Research centers</topic><topic>Review</topic><topic>Sickle cell disease</topic><topic>Task forces</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Watson, Michael S</creatorcontrib><creatorcontrib>Lloyd-Puryear, Michele A</creatorcontrib><creatorcontrib>Howell, R Rodney</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>International journal of neonatal screening</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Watson, Michael S</au><au>Lloyd-Puryear, Michele A</au><au>Howell, R Rodney</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Progress and Future of US Newborn Screening</atitle><jtitle>International journal of neonatal screening</jtitle><addtitle>Int J Neonatal Screen</addtitle><date>2022-07-18</date><risdate>2022</risdate><volume>8</volume><issue>3</issue><spage>41</spage><pages>41-</pages><issn>2409-515X</issn><eissn>2409-515X</eissn><abstract>Progress in newborn screening (NBS) has been driven for 60 years by developments in science and technology, growing consumer advocacy, the actions of providers involved in the care of rare disease patients, and by federal and State government funding and policies. With the current explosion of clinical trials of treatments for rare diseases, the pressure for expansion has grown, and concerns about the capacity for improvement and growth are being expressed. Genome and exome sequencing (GS/ES) have now opened more opportunities for early identification and disease prevention at all points in the lifespan. The greatest challenge facing NBS stems from the conditions most amenable to screening, and new treatment development is that we are screening for rare genetic diseases. In addition, understanding the spectrum of severity requires vast amounts of population and genomic data. We propose recommendations on improving the NBS system and addressing specific demands to grow its capacity by: better defining the criteria by which screening targets are established; financing the NBS system's responsiveness to opportunities for expansion, including engagement and funding from stakeholders; creating a national quality assurance, data, IT, and communications infrastructure; and improving intra-governmental communications. While our recommendations may be specific to the United States, the underlying issues should be considered when working to improve NBS programs globally.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35892471</pmid><doi>10.3390/ijns8030041</doi><orcidid>https://orcid.org/0000-0001-7776-9123</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2409-515X
ispartof International journal of neonatal screening, 2022-07, Vol.8 (3), p.41
issn 2409-515X
2409-515X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_effae7a4000a43fc8f581638bb840b54
source PubMed (Medline); Publicly Available Content Database (Proquest) (PQ_SDU_P3); Coronavirus Research Database
subjects Automation
clinical trials
Genes
Genetic disorders
Genetic testing
Genetics
Genomes
Information systems
Medical screening
Metabolism
Molecular biology
Newborn babies
newborn screening
Phenylketonuria
Public health
public health policy
Rare diseases
Research centers
Review
Sickle cell disease
Task forces
title The Progress and Future of US Newborn Screening
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T05%3A14%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Progress%20and%20Future%20of%20US%20Newborn%20Screening&rft.jtitle=International%20journal%20of%20neonatal%20screening&rft.au=Watson,%20Michael%20S&rft.date=2022-07-18&rft.volume=8&rft.issue=3&rft.spage=41&rft.pages=41-&rft.issn=2409-515X&rft.eissn=2409-515X&rft_id=info:doi/10.3390/ijns8030041&rft_dat=%3Cproquest_doaj_%3E2695288642%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c475t-3f120bf3b03b9443647c1933df67c375a709bec62bf274c34fb516002de293983%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2716550792&rft_id=info:pmid/35892471&rfr_iscdi=true